Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

NCT00064246 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

Post-transplant Lymphoproliferative Disorder
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Stage III Adult Burkitt Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage IV Adult Burkitt Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma
Waldenström Macroglobulinemia

Interventions

BIOLOGICAL: rituximab
RADIATION: indium In 111 ibritumomab tiuxetan
RADIATION: yttrium Y 90 ibritumomab tiuxetan

Sponsor

National Cancer Institute (NCI)